Factors affecting the stability of drugs and drug metabolites in biological matrices

Bioanalysis

Volumn 1, Issue 1, 2009, Pages 205-220

  Briscoe, Chad J ^a   Hage, David S ^b  

^a MDS Inc   (Canada)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEUTERIUM; DRUG;

BLOOD; CHEMICAL STRUCTURE; DRUG STABILITY; ENVIRONMENT; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; PH; PHOTOCHEMISTRY; REVIEW; STEREOISOMERISM; TEMPERATURE; URINE;

DEUTERIUM; DRUG STABILITY; ENVIRONMENT; HUMANS; HYDROGEN-ION CONCENTRATION; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PHARMACEUTICAL PREPARATIONS; PHOTOCHEMICAL PROCESSES; STEREOISOMERISM; TEMPERATURE;

EID: 78650668645     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.20     Document Type: Review

References (89)

1. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Rockville, MD, USA. US Department of Health and Human Services, FDA, CDER (2001).
2. Food and Drug Administration. Guidance for Industry: Safety Testing of Drug Metabolites. Rockville, MD, USA. US Department of Health and Human Services, FDA, CDER (2008).
3. Bansal S, DeStefano A. Key elements of bioanalytical method validation for small molecules. AAPS J. 9, 109-114 (2007).
4. Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPS J. 9, 117-122 (2007).
5. Viswanathan CT, Bansal S, Booth B et al. Workshop/Conference report-Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 9, 30-42 (2007).
6. Abou-Auda HS, Najjar TA, Al Khamis KI, Al-Hadiya BM, Ghilzai NM, Al-Fawzan NF. Liquid chromatographic assay of nifedipine in human plasma and its application to pharmacokinetic studies. J. Pharm. Biomed. Anal. 22, 241-249 (2000).
7. Van Harten J, Lodewijks MTM, Guyt-Scholten JW, Van Brummelen P, Breimer DD. Gas chromatographic determination of nisoldipine and one of its metabolites in plasma. J. Chromatogr. 423, 327-333 (1987).
8. Aronov PA, Hall LM, Dettmer K, Stephenson CB, Hammock BD. Metabolic profiling of major vitamin D metabolites using Diels-Alder derivitization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem. 391, 1917-1930 (2008).
9. Benhamou-Batut F, Demotes-Mainard F, Labat L, Vincon G, Bannwarth B. Determination of flunitrazepam in plasma by liquid chromatography J. Pharm. Biomed. Anal. 12, 931-936 (1994).
10. Skopp G, Potsch L, Mattern R, Aderjan R. Short-term stability of lysergic acid diethylamide (LSD), N-desmethyl-LSD, and 2-oxo-3-hydroxyl-LSD in urine, assessed by liquid chromatography-tandem mass spectrometry. Clin. Chem. 48, 1615-1618 (2002).
11. de Vries H, Beijersbergen van Henegouwen GMJ. Photochemical decomposition of lomefloxacin in vitro and in vivo. J. Photochem. Photobiol. B 58, 6-12 (2000).
12. Zhao JJ, Xie IH, Yang AY, Roadcap BA, Rogers JD. Quantitation of simvastatin and its p-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J. Mass Spectrom. 35, 1133-1143 (2000).
13. Buskin JN, Upton RA, Williams RL. Improved liquid-chromatography of aspirin, salicylate, and salicyluric acid in plasma, with a modification for determining aspirin metabolites in urine. Clin. Chem. 28, 1200-1203 (1982).
14. Wang N, Xu F, Zhang Z, Yang C, Sun X, Li J. Simultaneous determination of dipyridamole and salicylic acid in human plasma by high performance liquid chromatography-mass spectrometry. Biomed. Chromatogr. 22, 149-156 (2008).
15. Akay C, Degim IT, Sayal A, Aydin A, Ozkan Y, Gul H. Rapid and simultaneous determination of acetylsalicylic acid, paracetamol, and their degradation and toxic impurity products by HPLC in pharmaceutical dosage forms. Turk. J. Med. Sci. 38, 167-173 (2008).
16. Al-Hadidi KA, Oliver JS. Stability of temazepam in blood. Sci. Justice 35, 105-108 (1995).
17. Kjeld JM, Puah CM, Joplin GF. Rise of unconjugated sex hormones in human urine on storage. Clin. Chim. Acta 80, 285-291(1977).
18. El Mahjoub A, Staub C. Stability of benzodiazepines in whole blood samples stored at varying temperatures. J. Pharm. Biomed. Anal. 23, 1057-1063 (2000).
19. Clauwaert KM, Van Bocxlaer JF, De Leenheer AP. Stability study of the designer drugs "MDA, MDMA and MDEA" in water, serum, whole blood, and urine under various storage temperatures. Forensic Sci. Int. 124, 36-42 (2001).
20. Venneri MG, Del Rio G. Systematic study of long-term stability of 3, 4-dihydroxyphenylglycol in plasma for subsequent determination with liquid chromatography J. Chromatogr. B 802, 247-255 (2004).
21. Sparidans RW, Crul M, Schellens JHM, Beijnen JH. Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells. J. Chromatogr. B 780, 423-430 (2002).
22. Nirogi RVS, Kandikere VN, Shukla M, Mudigona K, Maurya S, Boosi R. Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20, 1695-1700 (2006).
23. Robinson A, Hillis J, Neal C, Leary AC. The validation of a bioanalytical method for the determination of clopidogrel in human plasma. J. Chromatogr. B 848, 344-354 (2007).
24. Singh SS, Sharma K, Barot D, Mohan PR, Lohray VB. Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic study. J. Chromatogr. B 821, 173-180 (2005).
25. Chollet DF, Goumaz L, Renard A et al. Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography J. Chromatogr. B 718, 163-175 (1998).
26. Stafford CG, St Claire RL. High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma. J. Chromatogr. B 663, 119-126 (1995).
27. de Bruijn P, Verwei J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B 698, 277-285 (1997).
28. Bom D, Curran DP, Kruszewski S et al. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J. Med. Chem. 43, 3970-3980 (2000).
29. Chen AY, Shih SJ, Garriques LN, Rothenberg ML, Hsiao M, Curran DP. Silatecan DB-67 is a novel DANN topoisomerase I-targeted radiation sensitizer. Mol. Cancer Ther. 4, 317-324 (2005).
30. Poujol S, Pinguet F, Malosse F. Sensitive HPLC-fluorescence method for irinotecan and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. Clin. Chem. 49, 1900-1908 (2003).
31. Andersson A, Ehrsson H. Stability of cisplatin and its monohydrated complex in blood, plasma and ultrafiltrate-implications for quantitative analysis. J. Pharm. Biomed. Anal. 13, 639-644 (1995).
32. Chung WY, On Chung JK, Szeto YT, Tomlinson B, Benzie IF. Plasma ascorbic acid: measurement, stability and clinical utility revisited. Clin. Biochem. 34, 623-627 (2001).
33. Hu OYP, Chang SP, Song YB, Chen KY, Law CK. Novel assay method for mitoxantrone in plasma, and its application in cancer patients. J. Chromatogr. 532, 337-350 (1990).
34. Priston MJ, Sewell GJ. Improved LC assay for the determination of mitozantrone in plasma: analytical considerations. J. Pharm. Biomed. Anal. 12, 1153-1162 (1994).
35. Matsuura K, Murai K, Fukano Y, Takashina H. Simultaneous determination of tiopronin and its metabolites in rat blood by LC-ESI-MS-MS using methyl acrylate for stabilization of thiol group. J. Pharm. Biomed. Anal. 22, 101-109 (2000).
36. Hasler F, Bourquin D, Brenneisen R, Bar T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm. Acta Helvetiae 72, 175-184 (1997).
37. Saxer C, Niina M, Nakashima A, Nagae Y, Masuda N. Simultaneous determination of levodopa and 3-O-methyldopa in human plasma by liquid chromatography with electrochemical detection. J. Chromatogr. B 802, 299-305 (2004).
38. Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP-IV) and related molecules in Type 2 diabetes. Front. Biosci. 13, 3648-3660 (2008).
39. Pei Z. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr. Opin. Drug Discovery Dev. 11, 512-532 (2008).
40. Sukovaty RL, Lee JW, Fox J et al. Quantification of recombinant human parathyroid hormone (rhPTH(1-84)) in human plasma by immunoassay: Commercial kit evaluation and validation to support pharmacokinetic studies. J. Pharm. Biomed. Anal. 42, 261-271 (2006).
41. van den Broek I, Sparidans RW, Schellens JHM, Beijnen JH. Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. J. Chromatogr. B 854, 245-259 (2007).
42. Wyss R, Bucheli F. Determination of cefetamet and its orally active ester, cefetamet pivoxyl, in biological fluids by high-performance liquid chromatography. J. Chromatogr. 430, 81-92 (1988).
43. Cao Y, Zhang M, Yu D, Shao J, Chen Y, Liu X. A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study. Anal. Bioanal. Chem. 391, 1063-1071 (2008).
44. Hansen J, Mork N, Bundgaard H. Phenyl carbamates of amino acids as prodrug forms for protecting phenols against first-pass metabolism. Int. J. Pharm. 81, 253-261 (1992).
45. Patel J, Katovich MJ, Sloan KB, Curry SH, Prankerd RJ. A prodrug approach to increasing the oral potency of a phenolic drug. Part 2. Pharmacodynamics and preliminary bioavailability of an orally administered O-(imidomethyl) derivative of 17β-estradiol. J. Pharm. Sci. 84, 174-178 (1995).
46. Patel JU, Prankerd RJ, Sloan KB. A prodrug approach to increasing the oral potency of a phenolic drug. 1. Synthesis, characterization, and stability of an O-(imidomethyl) derivative of 17β-estradiol. J. Pharm. Sci. 83, 1477-1481 (1994).
47. Rosing H, Doyle E, Davies BE, Beijnen JH. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total lactone plus carboxylate forms, in human plasma. J. Chromatogr. B 668, 107-115 (1995).
48. Akashi T, Nefuji T, Yoshida M, Hosoda J. Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography. J. Pharm. Biomed. Anal. 14, 339-346 (1996).
49. Ebner T, Heinzel G, Prox A et al. Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab. Dispos. 27, 1143-1149 (1999).
50. Chen J, Hsieh Y. Stabilizing drug molecules in biological samples. Ther. Drug Monit. 27, 617-624 (2005).
51. Takahashi M, Pang H, Kikuchi A et al. Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LC-MS/MS. Presented at: 54th ASMS Conference on Mass Spectrometry and Allied Topics. Seattle, Washington, USA, 28 May-1 June, 2006.
52. de Loor H, Naesens M, Verbeke K, Vanrenterghem Y, Kuypers DR. Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. Clin. Chim. Acta 389, 87-92 (2008).
53. Wainhaus SB, White RE, Dunn-Meynell K et al. Semi-quantitation of acyl glucuronides in early drug discovery by LC-MS/MS. Am. Pharm. Rev. 5, 86-92 (2002).
54. Murphy-Poulton SF, Boyle F, Gu XQ, Mather LE. Thalidomide enantiomers: determination in biological samples by HPLC and vancomycin-CSP. J. Chromatogr. B 831, 48-56 (2006).
55. Wu SE, Huskey WP, Borchardt RT, Schowen RL. Chiral instability at sulfur of S-adenosylmethionine. Biochemistry 22, 2828-2832 (1983).
56. Shi Y, Huang MH, Macor JE, Hughes DE. Characterization of the in vitro atropisomeric interconversion rates of an endothelin A antagonist by enantioselective liquid chromatography. J. Chromatogr. A 1078, 67-73 (2004).
57. Yan KX, Song H, Lo MW Determination of MK-0767 enantiomers in human plasma by normal phase LC-MS/MS. J. Chromatogr. B 813, 95-102 (2004).
58. Chavez-Eng CM, Constanzer ML, Matuszewski BK. High-performance liquid chromatographic-tandem mass spectrometric evaluation and determination of table iotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studies. J. Chromatogr. B 767, 117-129 (2002).
59. Moore DE. Photophysical and photochemical aspects of drug stability. In: Photostability of Drugs and Drug Formulations. Tonnesen HH (Ed.), CRC Press, Boca Raton, Florida, USA, 9-37 (2004).
60. Albini A, Fasani E. Rationalizing the photochemistry of drugs. In: Photostability of Drugs and Drug Formulations. Tonnesen HH (Ed.), CRC Press, Boca Raton, Florida, USA, 67-101 (2004).
61. Ferguson J. Fluoroquinolone photosensitization: A review of clinical and laboratory studies. Photochem. Photobiol. 62, 954-958 (1997).
62. Martinez LJ, Sik RH, Chignell CF. Fluoroquinolone antimicrobials: singlet oxygen, superoxide and phototoxicity Photochem. Photobiol. 67, 399-403 (1998).
63. Jemal M, Ouyang Z, Powell ML. Direct-injection LC-MS-MS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma. J. Pharm. Biomed. Anal. 23, 323-340 (2000).
64. Takahashi M, Pang H, Kikuchi A et al. Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LC-MS/MS. Presented at: 54th ASMS Conference on Mass Spectrometry and Allied Topics. Seattle, WA, USA, 28 May-1 June, 2006.
65. Rindgen D, Grotz D, Clarke NJ et al. The application of HPLC/tandem mass spectrometry for the assessment of acyl glucuronide metabolite formation in vitro and in vivo systems in a drug discovery environment. Am. Pharm. Rev. 4, 52-58 (2001).
66. Wainhaus S, White R, Dunn-Meynell K et al. Semi-quantitation of acyl glucuronides in early drug discovery by LC-MS/MS. Am. Pharm. Rev. 5, 86-92 (2002).
67. Stachulski AV, Harding JR, Lindon JC et al. Acyl glucuronides: biological activity, chemical reactivity, and chemical synthesis. J. Med. Chem. 49, 6931-6945 (2006).
68. Fura A, Harper TW, Zhang H, Fung L, Shyu WC. Shift in pH of biological fluids during storage and processing: effect on bioanalysis. J. Pharm. Biomed. Anal. 32, 513-522 (2003).
69. Anderson LS, Dzerk AM, Lin PP, Chen J, Lee J W. FK506 human EDTA whole blood validation. MDS Pharma Services Project 24636-1., 23 April 2003.
70. Benzie IFF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of 'antioxidant power': the FRAP assay. Anal. Biochem. 239, 70-76 (1996).
71. Jemal M, Hawthorne DJ. Quantitative determination of BMS186716, a thiol compound, in dog plasma by positive ion electrospray mass spectrometry after formation of the methyl acrylate adduct. J. Chromatogr. B 693, 109-116 (1997).
72. Jemal M, Khan S Teits DS et al. LC/MS/MS determination of omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor, and its sulfhydryl-and thioether-containing metabolites in human plasma. Anal. Chem. 73, 5450-5456 (2001).
73. Shimada K, Mitamura K. Derivitization of thiol containing compounds. J. Chromatogr. 659, 227-241 (1994)
74. Package insert in: Glucagon-Like Peptide-1 (Active) ELISA KIT 96-Well Plate (Cat. #EGLP-35K). Linco Research., 5 December 2005.
75. Williams K. Molecular asymmetry and its pharmacological consequences. Adv. Pharmacol. 22, 57-135 (1991).
76. Pepper C, Smith JH, Barrell KJ, Nicholles PJ, Hewlins MJE. Racemisation of drug enantiomers by benzylic proton abstraction at physiological pH. Chirality 6, 400-404 (1994).
77. Yang SK. Substitution and racemization of 3-hydroxy-and 3-alkoxy-1, 4-benzodiazepines in acidic aqueous solutions. Chirality 7, 365-375 (1995).
78. Shimada J, Hori T, Oguma T et al. Effects of protein binding on isomerization of ceftibuten. J. Pharm. Sci. 82, 461-465 (1993).
79. Eriksson T, Bjorkman S, Lyon AW, Raisys VA. Handling of blood samples for determination of thalidomide. Clin. Chem. 43, 1094-1096 (1997).
80. Molineux G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 23, S3-S8 (2003).
81. Lee JW. Bioanalytical methods used for pharmacokinetic evaluations of biotech macromolecule drugs: issues, assay approaches, and limitations. In: Pharmacokinetic and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Meibohm B (Ed.), Wiley-VCH, Weinheim, Germany, 147-180 (2006).
82. Calceti P, Salmaso S, Walker G, Bernkop-Schnurch A. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci. 22, 315-323 (2004).
83. Luthman K, Hacksell U. Peptides and peptidomimetics. In: A Textbook of Drug Design and Development. Krogsgaard-Larsen P, Liljefors T, Madsen U (Eds), Harwood Academic Publisher, Netherlands, 386-406 (1996).
84. Vabeno J, Leon T, Nielsen CU et al. Phe-Gly dipeptidomimetics designed for the di/tripeptide transporters PEPT1 and PEP2: synthesis and biological investigations. J. Med. Chem. 47, 1060-1069 (2004).
85. Wermuth CG. Molecular variations based on isosteric replacements. In: The Practice of Medicinal Chemistry. Wermuth CG (Ed.), The Practice of Medicinal Chemistry, Academic Press, London, UK, 203-336 (1996).
86. Ankersen M. Growth hormone secretagogues: discovery of small orally active molecules by peptidomimetic strategies. Prog. Med. Chem. 39, 173-214 (2002).
87. Steffansen B, Nielsen CU, Frokjaer S. Delivery aspects of small peptides and substrates for peptides transporters. Eur. J. Pharm. Biopharm. 60, 241-245 (2005).
88. Thayer AM. Filling a highly potent niche. Chem. Eng News 86, 28-32 (2008).
89. Rao HSP. Capping drugs: development of prodrugs. Resonance 8, 19-27 (2003).